Back

Temporal trends and regional differences of initial oral antiarrhythmic drug options in patients with new-onset atrial fibrillation: a report from the GLORIA-AF registry

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Novel and old treatments, evidence in large populations Antiarrhythmic Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Mr Bi Huang

The First Affiliated Hospital of Chongqing Medical University, Chongqing (China)

7 More presentations in this session

Presentation thumbnail
Ezetimibe use and mortality after myocardial infarction: a nationwide cohort study
Doctor V. Kyto (Turku, FI)
Abstract Slides Video
Presentation thumbnail
Lipid-lowering therapy with Inclisiran in the real-world setting: initial data from a national health care service
Associate Professor B. Zafrir (Haifa, IL)
Abstract Slides Video
Presentation thumbnail
Moderate-intensity statin combined with ezetimibe versus high-intensity statin monotherapy for secondary cardiovascular risk reduction: a systematic review and meta-analysis
Mr M. Kritya (Pune, IN)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of intravenous iron therapy in heart failure patients with iron deficiency: a systematic review and meta-analysis of randomized controlled trials
Doctor M. Abouzid (Poznan, PL)
Abstract Slides Video
Presentation thumbnail
Prognostic implications of guideline-directed medical therapy in functional mitral regurgitation: a meta-analysis
Doctor V. Anastasiou (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Novel and old treatments, evidence in large populations

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Temporal trends of prescription rates, dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in patients with atrial fibrillation
thumbnail
Congress Presentation
Comparative analysis of antiarrhythmic drugs following atrial fibrillation ablation
thumbnail
Congress Presentation
Impact of rhythm control strategy on outcomes in patients with first diagnosed atrial fibrillation in an 11-year real-world registry

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources